Dublin, London | 27 January 2021: Uniphar plc (the "Company" or "Uniphar") is pleased to announce the appointment of James ("Jim") Gaul and Elizabeth ("Liz") Hoctor to its Board as independent non-executive Directors with immediate effect.
Jim Gaul is an experienced executive and non-executive director with a strong track record in financial management in multinational pharmaceutical and healthcare sector companies. He is a former CFO of Sanofi Ireland, with thirty years' experience in companies across the healthcare value chain, from early stage/R&D pharma to patient-facing hospital services. Jim is also former CFO of Mount Carmel Private Hospital. Jim is a Certified Public Accountant with experience in financial management, successful strategic business modelling and achieving business growth. He has an interest and experience in the achievement of success through people and is an experienced change manager and mentor with a focus on building organisational structures to foster strong results and employee satisfaction. Jim is also an experienced board member with significant committee experience over the last twenty years on the Boards and Committees of Carraig Insurance Ltd, various Sanofi entities and Valeant Pharmaceuticals Ireland. Jim is currently a non-executive director of a number of OPKO Health subsidiaries.
Liz Hoctor is a qualified pharmacist with over thirty years' practical business experience and over twenty years' experience in advocacy and negotiation at both political and administrative levels of Government on behalf of the pharmacy profession. Liz was elected as President of the Irish Pharmacy Union ("IPU") from 2008-2010 and since 2013 has served as Professional Development and Learning Manager at the IPU. Liz owned and operated her own pharmacy from 1993 to 2005 in Mullingar. She has an in-depth understanding of the Irish, European and International Healthcare Systems and an extensive interest and expertise in the area of quality assurance and patient safety.
Other Board Developments
The Company also announces that Marie McConn is resigning from the Board with immediate effect and Padraic Staunton will resign from the Board at the Company's Annual General Meeting expected to take place in May and will not seek re-election. Both Marie and Padraic joined the Board in 2009 and each has played an invaluable role in driving the Board's agenda and in shareholder communications during their time on the Board.
The Company also announces the following non-executive director changes to the composition of the Committees of the Board with immediate effect:
· Jim Gaul and Liz Hoctor have been appointed to the Audit, Risk and Compliance Committee,
· Ger Penny has resigned from the Audit, Risk & Compliance Committee,
· Jim Gaul has been appointed to the Nominations and Governance Committee,
· Marie McConn has resigned from the Nominations and Governance Committee,
· Maurice Pratt and Padraic Staunton have resigned from the Remuneration Committee; and
· Jeff Berkowitz has been appointed to the Remuneration Committee.
The updated composition of the Committees of the Board will be available on the Company's website: www.uniphar.com.
Maurice Pratt, Chairman of Uniphar plc, commented:
"We are delighted to attract candidates of Jim Gaul and Liz Hoctor's experience to the Uniphar Board. Each with over 30 years' experience across the healthcare sector, Jim and Liz will add significantly to the depth and breadth of industry insights available to the Board and the senior management team in line with our growth strategy. On behalf of all our Directors, I would like to take this opportunity to warmly welcome Jim and Liz to the Board of Uniphar."
"I would also like to personally thank Marie McConn and Padraic Staunton for the very significant contribution they have each made as Board members over the past decade. Their experience and expertise were a great support to the Board since their appointments in 2009, and we wish them both well for the future."
Jim Gaul (an Irish citizen, aged 61 years) does not hold any ordinary shares or share options in the Company.